Survivin is a newly described apoptosis inhibitor that is expressed in many human cancers, but undetectable in terminally differentiated adult tissues. It has been shown that recombinant expression of Survivin conteracts apoptosis of B lymphocyte precursors deprived of interleukin 3 (IL-3), suggesting a potential role of Survivin in cancer therapy. Survivin is expressed in G2-M phase in a cell cycle-dependent manner and directly associated with mitotic spindle microtubules, suggesting a role in both apoptosis regulation and cell cycle progression.
Suitable for use in Western Blot and Immunofluorescence. Other applications have not been tested.
Western Blot: 0.5-4ug/ml
Optimal dilutions to be determined by the researcher.
Control Peptide: S8500-04A1
Storage and Stability:
May be stored at 4 degrees C for short-term only. For long-term storage, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.